bleomycin / Generic mfg. - LARVOL DELTA

Broad-Spectrum Protective Effects of Lyophilized FE002-Lu Lung Fibroblast Conditioned Medium Against Acute and Chronic Pulmonary Injury in Wistar Rats. (PubMed, Biomedicines) - " This GLP-compliant study evaluated the therapeutic efficacy spectrum of an off-the-shelf, clinical-grade, intratracheal lyophilized FE002-Lu lung fibroblast conditioned medium (LFCM) across five controlled Wistar rat models of induced lung injury: bleomycin (5 mg/kg), asbestos (100 µg/rat), hyperoxia (100% oxygen exposure), silica (30 mg/rat), and lipopolysaccharide (LPS, 4 mg/kg)... Lyophilized FE002-Lu LFCM acts as a potent, pleiotropic biologic that effectively resolves acute pulmonary inflammation and arrests progressive fibrotic remodeling across multiple distinct in vivo models. By overcoming the cold-chain and delivery limitations inherent to pulmonary live-cell therapies, this stable, cell-free secretome represents a highly scalable, "off-the-shelf" candidate poised for non-invasive, aerosolized clinical translation."

Journal • Preclinical • Fibrosis • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • CTSD • IL10 • IL1B • IL6 • TGFB1 • TIMP1 • TNFA

Safety and Feasibility of Endoscopic-Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: An Exploratory Randomised Clinical Trial. (PubMed, Cancers (Basel)) - "ECT is a technically feasible adjunct to neoadjuvant CRT for LARC. However, its efficacy and safety, particularly regarding surgical complications, remain unclear. Larger trials are needed to determine the role of ECT in multimodal neoadjuvant treatment."

Journal • Colorectal Cancer • Oncology • Pain • Rectal Cancer • Solid Tumor

Treatment Outcomes and Toxicity of Cisplatin-Etoposide-Based Regimens and Carboplatin-Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study. (PubMed, Cancers (Basel)) - "This study compared disease-free survival (DFS), treatment delivery, and toxicity between bleomycin-etoposide-cisplatin/etoposide-cisplatin (BEP/EP) and carboplatin-paclitaxel (CP) in the postoperative adjuvant setting. No statistically significant difference in DFS was detected between BEP/EP and CP, while distinct toxicity patterns were observed. Given the retrospective design, limited sample size, and potential for treatment-selection bias and residual confounding, these findings should be considered exploratory and should not be interpreted as evidence of equivalent efficacy between the regimens."

Journal • Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pain

Management and Clinical Outcomes of Liver Hemangiomas: A Retrospective Comparative Study of Transcatheter Arterial Embolization and Surgery. (PubMed, Medicina (Kaunas)) - " In this retrospective, non-randomized, single-center series, transarterial embolization was found to be a safe and effective minimally invasive treatment for liver hemangiomas and was associated with a shorter hospital stay. Because treatment allocation was not randomized, we cannot establish therapeutic equivalence between the two modalities, and the comparison should be regarded as descriptive; TAE represents an effective minimally invasive treatment option in appropriately selected patients and may be considered within a multidisciplinary treatment strategy, while surgery remains necessary in selected cases such as embolization failure, complicated lesion vascularization, or localization."

Clinical • Clinical data • Journal • Retrospective data • Oncology

A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis. (PubMed, Int J Mol Sci) - "Pirfenidone and nintedanib slow lung function decline, and the PDE4B inhibitor nerandomilast and treprostinil have recently shown promise as next-generation treatments. In conclusion, nintedanib retained robust antifibrotic activity when administered via dietary supplementation despite lower, but continuous, active plasma concentrations. Collectively, these findings indicate that optimizing drug delivery and absorption kinetics may achieve sustained therapeutic efficacy while reducing unnecessary exposure to supratherapeutic concentrations, thereby potentially improving tolerability."

Biomarker • Clinical • Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • FGF2 • MMP7

Yohimbine attenuates bleomycin-induced skin fibrosis by modulating the PI3K/Akt-MAPK signaling: an integrated network pharmacology and in vivo study. (PubMed, J Mol Histol) - "Histopathological, Masson's trichrome, and Sirius red/fast green collagen staining analysis further demonstrated that yohimbine treatment significantly (p < 0.05) reduced collagen deposition and restored normal skin architecture. Collectively, these findings demonstrate that yohimbine attenuates skin fibrosis by suppressing inflammatory and fibrotic responses, potentially through modulation of PI3K/Akt-MAPK signaling, and may represent a potential lead for further investigation in fibrotic skin disorders."

Journal • Preclinical • Dermatology • Fibrosis • Immunology • Inflammation • CTGF • FN1 • GSTP1 • HMOX1 • TNFA • VIM

Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanoma in ovo and ex vivo. (PubMed, Front Cell Dev Biol) - "Bleomycin-based ECT using a custom bipolar electrode induces substantial tumor damage in UM PDX in ovo and ex vivo. These findings support the potential application of bipolar electrode-based ECT for intraocular tumor treatment and provide a basis for further optimization of electrode design and translational investigation."

Journal • Preclinical • CNS Disorders • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • SOX10

Biomimetic Hydrogel Scaffold Loaded With Guluronate Oligosaccharides Promotes Lung Tissue Regeneration and Alleviates Pulmonary Fibrosis. (PubMed, Adv Healthc Mater) - "In vivo studies using rat models of acute lung injury (ALI) and mouse models of bleomycin (BLM)-induced pulmonary fibrosis demonstrated that the GelMA/HAMA hydrogel scaffold loaded with Oligo G promoted the repair of damaged lung tissue, alveolar regeneration, and angiogenesis after ALI. Moreover, it slowed the deterioration of pulmonary fibrosis and inflammation. The biomimetic GelMA/HAMA scaffold holds promise for promoting lung tissue repair after ALI and inhibiting pulmonary fibrosis progression."

Journal • Acute Lung Injury • Immunology • Lung Cancer • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • SMAD2 • TGFB1

Repeated instillations of bleomycin in male mice induce a perivascular remodeling at distance of fibrotic areas in the context of progressive pulmonary fibrosis. (PubMed, Animal Model Exp Med) - "We hypothesize that this remodeling, accompanied by a mild but significant increase in pulmonary artery media thickness, could be a precursor to pulmonary fibrosis-associated hypertension. These results suggest that this model could improve our understanding of pulmonary remodeling and vascular lesions in the early stages of pulmonary fibrosis."

Journal • Preclinical • Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Association of pyruvate metabolism-related genes with immune infiltration and prognostic value in lung adenocarcinoma. (PubMed, J Pharmacol Exp Ther) - "The low-risk group exhibited higher immune cell infiltration and potentially better immunotherapy responsiveness, whereas the high-risk group showed greater predicted sensitivity to bleomycin and doxorubicin. Functional experiments further provided preliminary evidence linking ALDH1B1 to malignant cellular phenotypes and glycolytic activity. Further prospective and functional validation of the complete signature is required."

IO biomarker • Journal • Tumor mutational burden • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TMB

Comparative efficacy and safety of pharmacologic, laser, and combination therapies for infantile hemangioma: a systematic review and network meta-analysis with evidence certainty assessment. (PubMed, Front Pharmacol) - "Regarding the primary endpoint, intralesional bleomycin combined with oral propranolol yielded significantly higher excellent response rates than oral propranolol alone (RR = 1.55, 95% CI 1.28-1.89; high certainty). Topical timolol with intralesional lauromacrogol (RR = 7.98, 95% CI 1.52-41.79) and oral propranolol with corticosteroids (RR = 2.00, 95% CI 1.03-3.88) showed higher excellent response rates, supported by moderate-certainty evidence...Oral atenolol was associated with numerically lower recurrence rates compared to oral propranolol, but the difference did not reach statistical significance (RR = 0.64, 95% CI 0.32-1.28; moderate certainty)...Defining precise risk-benefit profiles requires rigorous head-to-head trials utilizing uniform outcome measures. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261388356; Identifier: CRD420261388356."

Journal • Retrospective data • Review • Oncology

Case Report: A rare mimicker of traumatic brachial plexopathy: intramuscular venous malformation of the subscapularis muscle. (PubMed, Front Surg) - "In view of difficult surgical access for removal associated with high risks of iatrogenic neurological injury, fluoroscopy-guided percutaneous bleomycin sclerotherapy was performed. Significant neurological recovery was observed post-intervention in conjunction with intensive rehabilitation. This case report outlines the diagnostic clues, management challenges, and functional outcomes of a right subscapularis intramuscular VM causing secondary compressive brachial plexopathy."

Journal • Pain

Who needs bleomycin in classic Hodgkin lymphoma? Comment on: "Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD". (PubMed, Haematologica) - "Not available."

Journal • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Inhibition of Extracellular Tissue Transglutaminase (TG2) Activity Attenuates Development of Pulmonary Fibrosis in a Novel Rabbit Model. (PubMed, Am J Physiol Lung Cell Mol Physiol) - "Treatment with TG2 inhibitory antibody rbBB7, a rabbitized version of the human therapeutic antibody zampilimab, reduced TG2 activity and attenuated fibrosis by 50% when used in either a prevention or treatment strategy, which was associated, with reductions in interstitial collagen accumulation. TG2 has previously been reported to contribute to pulmonary fibrosis in the mouse bleomycin model, leading to the conclusion that TG2 contributes significantly to the pathogenesis of pulmonary fibrosis as demonstrated in human tissue specimens and two independent animal models with different fibrotic stimuli. Blockade of TG2 extracellular crosslinking activity with a therapeutic antibody significantly attenuated the development of fibrosis when given in a prevention strategy or treatment strategy. Blockade of extracellular TG2 activity has exciting therapeutic potential."

Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGFB1 • TGM2

Targeting the Snail1-ATGL-Ferroptosis-EMT Axis via AKT-GSK3β Signaling: Low-Dose Colchicine Attenuates Idiopathic Pulmonary Fibrosis. (PubMed, Eur J Pharmacol) - "These findings identify ATGL as an epithelial checkpoint that modulates ferroptosis susceptibility and EMT under fibrotic stress and reveal Snail1-dependent regulation of ferroptosis as a previously unappreciated noncanonical mechanism of EMT regulation. This study provides novel mechanistic insight into the actions of low-dose COL, supporting its translational relevance in IPF."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • GSK3B • HDAC1 • HDAC2 • SNAI1 • TGFB1

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Intralesional Bleomycin for Genital Lymphedema-Associated Lymphatic Malformations and Lymphorrhea. (PubMed, Aesthetic Plast Surg) - "Intralesional bleomycin sclerotherapy appears to be a safe and effective minimally invasive treatment option for genital lymphedema-associated lymphatic malformations and lymphorrhea. This study provides additional clinical evidence for the management of this underrecognized complication of genital lymphedema."

Journal • Gynecologic Cancers • Hematological Disorders • Lymphoma • Oncology

Chlorogenic Acid Attenuates Bleomycin-Induced Pulmonary Fibrosis in a Murine Model by Modulating TGF-β1 Expression. (PubMed, Adv Respir Med) - "CGA exerts important therapeutic effects by decreasing the expression of TGF-β1 and the activation of myofibroblasts, indicating that this natural polyphenol is a promising candidate for mitigating the progression of pulmonary fibrosis."

Journal • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Interstitial Lung Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • COL1A1 • TGFB1

Expert consensus on embolization and sclerotherapy with fibrin glue combined with pingyangmycin for oral and maxillofacial vascular malformations (PubMed, Shanghai Kou Qiang Yi Xue) - "Fibrin glue combined with pingyangmycin or bleomycin embolosclerotherapy technology treats vascular malformations via the mechanism of immediate embolization, sustained drug release and synergistic fibrosis...This consensus document elaborated on the background, basic research, and clinical studies related to fibrin glue combined with pingyangmycin embolosclerotherapy, and discusses its mechanism of action in eliminating vascular malformations. By integrating the latest research findings and clinical experiences in the field, as well as incorporating discussions and opinions from experts across multiple medical institutions in China, this consensus provides guidance on clinical applications including indications and contraindications, pre-treatment preparations, procedural standards, prevention and management of potential complications, and comprehensive implementation, so as to serve as a reference for clinical practice."

Journal • Cardiovascular • CNS Disorders • Fibrosis • Immunology

WHEN BLEOMYCIN STRIKES BACK: RARE DELAYED PULMONARY HEMORRHAGE AFTER HODGKIN LYMPHOMA TREATMENT (CHEST 2026) - No abstract available

Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Variant Histology in Pediatric NLPBL: Adverse Biology Mitigated by R-CHOP, Including Feasible Early-Stage De-Escalation (SOHO 2026) - "Variant histology identifies a biologically and clinically higher-risk subgroup of pediatric NLPBL. However, this adverse impact appears to be mitigated by R-CHOP, with excellent outcomes—even in patients with variant histology. Our findings further suggest that risk-adapted de-escalation may be feasible in early-stage disease, including observation after complete resection and reduced-cycle R-CHOP for unresected stage 1–2 disease, without an apparent loss of efficacy."

Clinical • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Surgical debulking and electrochemotherapy, including a tetrapolar single-needle electrode, are associated with clinical benefit in dogs with intranasal tumors. (PubMed, J Am Vet Med Assoc) - "Dogs were included if they underwent at least 1 surgical procedure combined with intraoperative bleomycin-based ECT using a multielectrode approach and had a minimum follow-up period of 2 months...These findings support further prospective investigation of this approach for intranasal tumors in dogs. This approach may represent a treatment option for dogs with locally advanced intranasal tumors, particularly when radiotherapy is unavailable."

Journal • Infectious Disease • Oncology • Solid Tumor

Nintedanib lacks efficacy in a spirometry-confirmed and bleomycin-induced mouse model of idiopathic pulmonary fibrosis (ERS 2026) - "Collectively, these findings challenge the use of nintedanib as a benchmarking drug in the single-dose BLEO-IPF mouse model."

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • COL1A1 • LGALS3

Late Breaking Abstract - Slow-Releasing Hydrogen Sulphide Donor GYY4137, Alone or in Combination with Pirfenidone, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice (ERS 2026) - "These findings extend our previous observations on i.n. GYY4137 treatment and suggests a superior option to PIR for consideration as an add-on therapy. This work has been supported by the Scientific Research Projects Coordination Unit of Hacettepe University under grant number TOA-2025-21834."

Combination therapy • Late-breaking abstract • Preclinical • Fibrosis • Immunology • Inflammation • Interstitial Lung Disease • Respiratory Diseases

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial (ASH 2023) - P3 | "INTRODUCTION The GHSG-HD21 trial for newly diagnosed adult patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) compares the BrECADD regimen (Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar­bazine, prednisone) in a PET adapted approach. Importantly, while the larger patient cohort of PET2-negative patients achieves a very high 3-yr PFS of 97% with a very short and safe 12-week treatment, this benefit was also observed for PET2-positive patients. In conclusion, the optimized risk-benefit ratio of the BrECADD regimen combined with the individualized PET2-guided treatment duration sets a new benchmark for the treatment of adult patients with newly diagnosed advanced stage cHL"

P3 data • Classical Hodgkin Lymphoma • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukopenia • Lymphoma • Oncology • Thrombocytopenia